Related Experiment Videos
Cerebrospinal fluid beta 2-microglobulin in neurological disorders
Acta Neurologica Scandinavica
|December 1, 1978
Summary
Beta-2-microglobulin levels in cerebrospinal fluid (CSF) showed potential elevation in neurological conditions like brain infarcts and infections. CSF beta-2-microglobulin may serve as a biomarker, though further research is needed.
Area of Science:
- Neurology
- Biochemistry
- Clinical Diagnostics
Background:
- Beta-2-microglobulin (B2M) is a protein found on cell surfaces.
- Its levels in cerebrospinal fluid (CSF) may indicate neurological disease activity.
- Understanding B2M dynamics in CSF is crucial for diagnosing central nervous system disorders.
Purpose of the Study:
- To investigate the concentration and diagnostic utility of beta-2-microglobulin in CSF.
- To compare CSF B2M levels across various neurological conditions.
- To assess the ratio of CSF to serum B2M as a potential biomarker.
Main Methods:
- CSF and serum samples were collected from 167 patients across 14 diagnostic categories.
- Beta-2-microglobulin concentrations were measured using established laboratory assays.
- Statistical analysis was performed to compare B2M levels between groups.
Main Results:
- The control group had a mean CSF B2M of 1.15 +/- 0.37 mg/L.
- Elevated CSF B2M concentrations were observed in patients with brain infarct, CNS infection, and polyneuropathy.
- No significant differences in serum B2M levels were found across diagnostic categories.
Conclusions:
- CSF beta-2-microglobulin shows potential as a biomarker for certain neurological diseases.
- Further investigation is warranted to establish the diagnostic significance of CSF B2M.
- The CSF/serum B2M ratio did not prove statistically significant in this study.